Bronchogen

Overview

Bronchogen is a synthetic tetrapeptide bioregulator with the amino acid sequence Ala-Glu-Asp-Leu (AEDL, H-Ala-Glu-Asp-Leu-OH), developed by Professor Vladimir Khavinson's team at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. It belongs to the Khavinson short-peptide (cytogen) family, specifically the member associated with bronchial-pulmonary tissue. The compound is listed in PubChem (CID 11690869, independently re-confirmed to exist in this pass; molecular formula C18H30N4O9); the molecular weight has been cross-checked and matches between PubChem (approximately 446.5 Da via the PUG-REST data interface) and independent third-party vendor technical data sheets (e.g., NovoProLabs, listing 446.44 Da). Note: PubChem also carries a second entry, CID 471572; independent structural verification (InChIKey comparison) in this pass found its N-terminus is glutamic acid rather than alanine (H-Glu-Asp-Leu-Ala-OH) — a distinct isomer with the same molecular formula but a different residue order, not a duplicate naming of the same compound. This entry is unrelated to any of Bronchogen's three core publications and may reflect a vendor-sourced mix-up; it should not be treated as an equivalent entry for Bronchogen. This class of short peptides is hypothesized to regulate gene expression by binding specific DNA motifs, and has been studied in vitro and in animal models for tissue-specific effects on bronchial epithelial cell differentiation. There are currently three core peer-reviewed publications (a 2011 DNA-binding mechanism study, a 2012 cell differentiation study, and a 2015 rat COPD model study), all independently re-verified to exist via PubMed/Springer Nature Link in this pass. All three originate from the Khavinson team and Russian/St. Petersburg research institutions; the evidence base remains limited in scale, and no double-blind human trials have been reported in the English-language literature. Bronchogen is offered as a lyophilized linear tetrapeptide with a ≥99.0% HPLC catalogue target. Ask sales for the matching batch COA; it records the analytical work actually completed. Any sequence evidence, water, residual-solvent, endotoxin, or raw-data requirement must be included in the agreed written scope before quotation.

Applications & buyer fit

Buyers for longevity-class peptides span research labs working on telomere, collagen, and circadian-rhythm models, plus cosmetic-formulation OEMs incorporating peptides like GHK-Cu into anti-aging finished products. Copper peptides in particular require attention to chelator-free water and EDTA-free buffers in downstream formulation work, incompatibility there is the most common cause of "the peptide didn't work" support tickets in this class.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

(research compound · identity on COA)

Molecular Formula

C18H30N4O9

Molecular Weight

446.44 g/mol

Sequence

Ala-Glu-Asp-Leu

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

20 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 30 minutes

MOQ

On request

Lead time

14–21 days

Storage

-20°C lyophilized; 2–8°C reconstituted, protect from light

Certificate of Analysis

Representative COA previews for Bronchogen; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

Bronchogen

VD260428-BRON038 · 98.98%

Regulatory note

Research-use-only reference material; not for human or veterinary use.

Selected literature

1. Khavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781-791.
2. Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, Surkova EA, Platonova IS, Titova ON. Modulating effect of peptide therapy on the morphofunctional state of bronchial epithelium in rats with obstructive lung pathology. Bull Exp Biol Med. 2015;159(5):685-688.
3. Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Mosc). 2015;80(3):310-322.
4. Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, Khachidze DG, Lomidze EM, Jokhadze TA, Lezhava TA. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bull Exp Biol Med. 2011;150(3):375-377.
5. Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053.

Frequently asked questions